Curevac announces financial results for the third quarter and first nine months of 2023 and provides business update

Curevac announces financial results for the third quarter and first nine months of 2023 and provides business update enrollment completed for phase 2 covid-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024 first participant dosed in seasonal flu phase 2 study with potentially differentiated multivalent candidate; €15 million milestone payment by gsk triggered phase 1 study in glioblastoma well on track with opening of third dose level for cvgbm, curevac's multiepitope cancer vaccine candidate preclinical data with multiepitope construct in oncology shows strong t cells responses and significantly extended survival in checkpoint-inhibitor resistant melanoma model infringement ruling on four intellectual property rights postponed by regional court dÜsseldorf pending separate validity ruling in german patent litigation against biontech; postponement suggests court will find all four rights to be infringed the rna printer® achieved first milestone, obtaining manufacturing license for gmp-grade mrna manufacturing in cancer vaccine development chief business and commercial officer to leave curevac at the end of his term, effective november 30, 2023 cash and cash equivalents position of €464.1 million as of september 30, 2023 curevac to host conference call and webcast today at 9 a.m. et / 3 p.m.
CVAC Ratings Summary
CVAC Quant Ranking